Founded by mass spectrometry researchers affiliated with Oregon State University, E-Msion Inc's ExD Cell is the culmination of over a decade of research and development. With the objective being to advance proteomics research by improving the accessibility of electron-based fragmentation in mass spectrometry, the firm offers a device - designated the ExD Cell - that enables a type of fragmentation, similar to electron-capture dissociation (ECD), as an add-on to virtually any type of mass spectrometer. This unique type of fragmentation produced by the device enables fast, comprehensive characterization of ions without the experimental complexity of other competing technologies on the market today. e-MSion is the first to make ECD technically feasible on instruments that are in the low- to mid-price range. As a result, the device makes ECD more accessible for the masses. The universally-compatible ExD Cell device can give life science researchers the ability to more comprehensively characterize their molecules of interest. ____ In March 2023, it was announced that the firm had been acquired by Agilent Technologies.
